Effectiveness of integrating HIV prevention within sexual reproductive health services with or without peer support among adolescents and young adults in rural KwaZulu-Natal, South Africa (Isisekelo Sempilo): 2 × 2 factorial, open-label, randomised controlled trial.

IF 12.8 1区 医学 Q1 IMMUNOLOGY Lancet Hiv Pub Date : 2024-07-01 DOI:10.1016/S2352-3018(24)00119-X
Maryam Shahmanesh, Natsayi Chimbindi, Jacob Busang, Glory Chidumwa, Nondumiso Mthiyani, Carina Herbst, Nonhlanhla Okesola, Jaco Dreyer, Thembelihle Zuma, Manono Luthuli, Dumsani Gumede, Siphesihle Hlongwane, Simphiwe Mdluli, Sithembile Msane, Theresa Smit, Jean-Michel Molina, Thandeka Khoza, Ngundu Osee Behuhuma, Nuala McGrath, Janet Seeley, Guy Harling, Lorraine Sherr, Andrew Copas, Kathy Baisley
{"title":"Effectiveness of integrating HIV prevention within sexual reproductive health services with or without peer support among adolescents and young adults in rural KwaZulu-Natal, South Africa (Isisekelo Sempilo): 2 × 2 factorial, open-label, randomised controlled trial.","authors":"Maryam Shahmanesh, Natsayi Chimbindi, Jacob Busang, Glory Chidumwa, Nondumiso Mthiyani, Carina Herbst, Nonhlanhla Okesola, Jaco Dreyer, Thembelihle Zuma, Manono Luthuli, Dumsani Gumede, Siphesihle Hlongwane, Simphiwe Mdluli, Sithembile Msane, Theresa Smit, Jean-Michel Molina, Thandeka Khoza, Ngundu Osee Behuhuma, Nuala McGrath, Janet Seeley, Guy Harling, Lorraine Sherr, Andrew Copas, Kathy Baisley","doi":"10.1016/S2352-3018(24)00119-X","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Approximately 200 000 South Africans acquired HIV in 2021 despite the availability of universal HIV test and treat and pre-exposure prophylaxis (PrEP). The aim of this study was to test the effectiveness of sexual and reproductive health services or peer support, or both, on the uptake of serostatus neutral HIV services or reduction of sexually transmissible HIV.</p><p><strong>Methods: </strong>We did an open-label, 2 × 2 randomised factorial trial among young people in a mostly rural area of KwaZulu-Natal, South Africa. Inclusion criteria included being aged 16-29 years, living in the mapped geographical areas that were accessible to the area-based peer navigators, being willing and able to provide informed consent, and being willing to provide a dried blood spot for anonymous HIV testing and HIV viral load measurement at 12 months. Participants were randomly allocated by computer-generated algorithm to one of four groups: those in the standard-of-care group were referred to youth-friendly services for differentiated HIV prevention (condoms, universal HIV test and treat with antiretroviral therapy, and PrEP if eligible); those in the sexual and reproductive health services group received baseline self-collected specimens for sexually transmitted infection (STI) testing and referral to integrated sexual and reproductive health and HIV prevention services; those in the peer support group were referred to peer navigators for health promotion, condom provision, and facilitation of attendance for differentiated HIV prevention services; and those in the final group received a combination of sexual and reproductive health services and peer support. Coprimary outcomes were linkage to clinical services within 60 days of enrolment, proportion of participants who had sexually transmissible HIV at 12 months after enrolment, and proportion of sampled individuals who consented to participation and gave a dried blood spot for HIV testing at 12 months. Logistic regression was used for analyses, and adjusted for age, sex, and rural or peri-urban area of residence. This study is registered with ClinicalTrials.gov (NCT04532307) and is closed.</p><p><strong>Findings: </strong>Between March 2, 2020, and July 7, 2022, 1743 (75·7%) of 2301 eligible individuals were enrolled and followed up. 12-month dried blood spots were collected from 1168 participants (67·0%). The median age of the participants was 21 years (IQR 18-25), 51·4% were female, and 51·1% had secondary level education. Baseline characteristics and 12-month outcome ascertainment were similar between groups. 755 (43·3%) linked to services by 60 days. 430 (49·8%) of 863 who were in the sexual reproductive health services group were linked to care compared with 325 (36·9%) of 880 who were not in the sexual and reproductive health services group (adjusted odds ratio [aOR] 1·68; 95% CI 1·39-2·04); peer support had no effect: 385 (43·5%) of 858 compared with 370 (43·1%) of 885 (1·02, 0·84-1·23). At 12 months, 227 (19%) tested ELISA-positive for HIV, of whom 41 (18%) had viral loads of 400 copies per mL; overall prevalence of transmissible HIV was 3·5%. 22 (3·7%) of 578 participants in the sexual and reproductive health services group had transmissible HIV compared with 19 (3·3%) of 590 not in the sexual and reproductive health services group (aOR 1·12; 95% CI 0·60-2·11). The findings were also non-significant for peer support: 21 (3·3%) of 565 compared with 20 (3·3%) of 603 (aOR 1·03; 95% CI 0·55-1·94). There were no serious adverse events or deaths during the study.</p><p><strong>Interpretation: </strong>This study provides evidence that STI testing and sexual and reproductive health services create demand for serostatus neutral HIV prevention in adolescents and young adults in Africa. STI testing and integration of HIV and sexual health has the potential to reach those at risk and tackle unmet sexual health needs.</p><p><strong>Funding: </strong>US National Institute of Health, Bill & Melinda Gates Foundation, and 3ie.</p>","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"11 7","pages":"e449-e460"},"PeriodicalIF":12.8000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Hiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/S2352-3018(24)00119-X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Approximately 200 000 South Africans acquired HIV in 2021 despite the availability of universal HIV test and treat and pre-exposure prophylaxis (PrEP). The aim of this study was to test the effectiveness of sexual and reproductive health services or peer support, or both, on the uptake of serostatus neutral HIV services or reduction of sexually transmissible HIV.

Methods: We did an open-label, 2 × 2 randomised factorial trial among young people in a mostly rural area of KwaZulu-Natal, South Africa. Inclusion criteria included being aged 16-29 years, living in the mapped geographical areas that were accessible to the area-based peer navigators, being willing and able to provide informed consent, and being willing to provide a dried blood spot for anonymous HIV testing and HIV viral load measurement at 12 months. Participants were randomly allocated by computer-generated algorithm to one of four groups: those in the standard-of-care group were referred to youth-friendly services for differentiated HIV prevention (condoms, universal HIV test and treat with antiretroviral therapy, and PrEP if eligible); those in the sexual and reproductive health services group received baseline self-collected specimens for sexually transmitted infection (STI) testing and referral to integrated sexual and reproductive health and HIV prevention services; those in the peer support group were referred to peer navigators for health promotion, condom provision, and facilitation of attendance for differentiated HIV prevention services; and those in the final group received a combination of sexual and reproductive health services and peer support. Coprimary outcomes were linkage to clinical services within 60 days of enrolment, proportion of participants who had sexually transmissible HIV at 12 months after enrolment, and proportion of sampled individuals who consented to participation and gave a dried blood spot for HIV testing at 12 months. Logistic regression was used for analyses, and adjusted for age, sex, and rural or peri-urban area of residence. This study is registered with ClinicalTrials.gov (NCT04532307) and is closed.

Findings: Between March 2, 2020, and July 7, 2022, 1743 (75·7%) of 2301 eligible individuals were enrolled and followed up. 12-month dried blood spots were collected from 1168 participants (67·0%). The median age of the participants was 21 years (IQR 18-25), 51·4% were female, and 51·1% had secondary level education. Baseline characteristics and 12-month outcome ascertainment were similar between groups. 755 (43·3%) linked to services by 60 days. 430 (49·8%) of 863 who were in the sexual reproductive health services group were linked to care compared with 325 (36·9%) of 880 who were not in the sexual and reproductive health services group (adjusted odds ratio [aOR] 1·68; 95% CI 1·39-2·04); peer support had no effect: 385 (43·5%) of 858 compared with 370 (43·1%) of 885 (1·02, 0·84-1·23). At 12 months, 227 (19%) tested ELISA-positive for HIV, of whom 41 (18%) had viral loads of 400 copies per mL; overall prevalence of transmissible HIV was 3·5%. 22 (3·7%) of 578 participants in the sexual and reproductive health services group had transmissible HIV compared with 19 (3·3%) of 590 not in the sexual and reproductive health services group (aOR 1·12; 95% CI 0·60-2·11). The findings were also non-significant for peer support: 21 (3·3%) of 565 compared with 20 (3·3%) of 603 (aOR 1·03; 95% CI 0·55-1·94). There were no serious adverse events or deaths during the study.

Interpretation: This study provides evidence that STI testing and sexual and reproductive health services create demand for serostatus neutral HIV prevention in adolescents and young adults in Africa. STI testing and integration of HIV and sexual health has the potential to reach those at risk and tackle unmet sexual health needs.

Funding: US National Institute of Health, Bill & Melinda Gates Foundation, and 3ie.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在南非夸祖鲁-纳塔尔省农村地区的青少年和年轻成年人中,将艾滋病预防纳入性生殖健康服务并提供或不提供同伴支持的效果(Isisekelo Sempilo):2 × 2因子、开放标签、随机对照试验。
背景:尽管南非普及了艾滋病毒检测和治疗以及暴露前预防疗法(PrEP),但 2021 年仍有约 20 万南非人感染了艾滋病毒。本研究的目的是测试性健康和生殖健康服务或同伴支持,或两者对接受血清状态中立的艾滋病毒服务或减少性传播艾滋病毒的有效性:我们在南非夸祖鲁-纳塔尔省(KwaZulu-Natal)一个以农村为主的地区,对年轻人进行了一项开放标签、2 × 2 随机因子试验。纳入标准包括年龄在 16-29 岁之间,居住在以地区为基础的同伴导航员可以到达的地图地理区域内,愿意并能够提供知情同意书,愿意提供干血斑进行匿名 HIV 检测和 12 个月的 HIV 病毒载量测量。参与者通过计算机生成的算法被随机分配到四个组别中的一组:标准护理组的参与者被转介到青年友好型服务机构,接受有区别的 HIV 预防服务(安全套、普及 HIV 检测和抗逆转录病毒疗法以及 PrEP(如果符合条件));性健康和生殖健康服务组的参与者接受基线自采标本,进行性传播感染(STI)检测,并被转介到综合的性健康和生殖健康及 HIV 预防服务机构;同伴支持组:转诊给同伴指导员,以促进健康、提供安全套并协助参加有区别的 HIV 预防服务;最后一组:接受性与生殖健康服务和同伴支持的综合服务。主要结果包括:入组后 60 天内与临床服务的联系、入组后 12 个月内感染性传播 HIV 的参与者比例、同意参与并在 12 个月内提供干血样进行 HIV 检测的抽样者比例。分析采用逻辑回归法,并对年龄、性别、农村或城郊居住区进行了调整。该研究已在 ClinicalTrials.gov (NCT04532307) 上注册,并已结束:在 2020 年 3 月 2 日至 2022 年 7 月 7 日期间,2301 名符合条件的人中有 1743 人(75-7%)入选并接受了随访。从 1168 名参与者(67-0%)中采集了 12 个月的干血斑。参与者的年龄中位数为 21 岁(IQR 18-25),51-4% 为女性,51-1% 接受过中等教育。各组的基线特征和 12 个月的结果确认情况相似。755 人(43-3%)在 60 天前与服务机构建立了联系。在接受性健康和生殖健康服务的 863 人中,有 430 人(49-8%)接受了治疗,而在未接受性健康和生殖健康服务的 880 人中,有 325 人(36-9%)接受了治疗(调整后的几率比 [aOR] 1-68;95% CI 1-39-2-04);同伴支持没有影响:858 人中有 385 人(43-5%)接受了治疗,而 885 人中有 370 人(43-1%)接受了治疗(1-02,0-84-1-23)。在 12 个月时,227 人(19%)的艾滋病毒 ELISA 检测呈阳性,其中 41 人(18%)的病毒载量为每毫升 400 个拷贝;可传播艾滋病毒的总体流行率为 3-5%。在性健康与生殖健康服务组的 578 名参与者中,有 22 人(3-7%)感染了可传播的 HIV,而在非性健康与生殖健康服务组的 590 名参与者中,有 19 人(3-3%)感染了可传播的 HIV(aOR 1-12;95% CI 0-60-2-11)。在同伴支持方面,研究结果也不显著:565 人中有 21 人(3-3%)接受了同伴支持,而 603 人中有 20 人(3-3%)接受了同伴支持(aOR 1-03;95% CI 0-55-1-94)。研究期间没有发生严重不良事件或死亡:这项研究提供的证据表明,性传播感染检测以及性健康和生殖健康服务为非洲青少年和年轻成年人的血清状态中性艾滋病预防创造了需求。性传播感染检测和艾滋病与性健康的结合有可能惠及高危人群,并解决未得到满足的性健康需求:美国国立卫生研究院、比尔及梅林达-盖茨基金会和 3ie.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Lancet Hiv
Lancet Hiv IMMUNOLOGYINFECTIOUS DISEASES&-INFECTIOUS DISEASES
CiteScore
19.90
自引率
4.30%
发文量
368
期刊介绍: The Lancet HIV is an internationally trusted source of clinical, public health, and global health knowledge with an Impact Factor of 16.1. It is dedicated to publishing original research, evidence-based reviews, and insightful features that advocate for change in or illuminates HIV clinical practice. The journal aims to provide a holistic view of the pandemic, covering clinical, epidemiological, and operational disciplines. It publishes content on innovative treatments and the biological research behind them, novel methods of service delivery, and new approaches to confronting HIV/AIDS worldwide. The Lancet HIV publishes various types of content including articles, reviews, comments, correspondences, and viewpoints. It also publishes series that aim to shape and drive positive change in clinical practice and health policy in areas of need in HIV. The journal is indexed by several abstracting and indexing services, including Crossref, Embase, Essential Science Indicators, MEDLINE, PubMed, SCIE and Scopus.
期刊最新文献
Global, regional, and national burden of HIV/AIDS, 1990-2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021. Correction to Lancet HIV 2024; 11: e783-90. HIV-related outcomes among migrants living in Europe compared with the general population: a systematic review and meta-analysis. Outcomes and gaps in HIV care for migrants in Europe. Correction to Lancet HIV 2024; 11: e736-45.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1